Hypothesis

Chronic elevation of the microbial metabolite δ‑valerobetaine in aging drives excessive perineuronal net (PNN) formation on hippocampal parvalbumin‑positive interneurons, locking brain microstates B and D into a rigid, hypersynchronous mode. Supplementation with a butyrate‑producing probiotic strain will lower δ‑valerobetaine, increase colonic butyrate, and via the vagus nerve suppress microglial TGF‑β signaling, thereby reducing PNN deposition and restoring flexible microstate dynamics.

Mechanistic Rationale

• Aging microbiota shows increased δ‑valerobetaine, which directly impairs learning and memory [https://pmc.ncbi.nlm.nih.gov/articles/PMC10174391/].
• Butyrate inhibits histone deacetylases, promoting an anti‑inflammatory microglial phenotype and downregulating TGF‑β, a key driver of PNN synthesis [https://pmc.ncbi.nlm.nih.gov/articles/PMC2717558/].
• Vagal afferents transmit gut‑derived signals to the nucleus tractus solitarius, influencing locus coeruleus norepinephrine release that modulates hippocampal plasticity [https://pmc.ncbi.nlm.nih.gov/articles/PMC12667136/].
• Reduced PNN density re‑opens critical‑period‑like plasticity windows, allowing microstate B and D to shift fluidly in response to novelty, as seen after enzymatic PNN removal [https://pmc.ncbi.nlm.nih.gov/articles/PMC12628600/].

Testable Predictions

1. Older adults receiving a butyrate‑enhancing probiotic will exhibit ↓ fecal δ‑valerobetaine and ↑ serum butyrate after 8 weeks.
2. Concurrently, resting‑state EEG will show decreased dwell time and transition entropy rigidity in microstates B and D, correlating with improved performance on the Wisconsin Card Sorting Test.
3. High‑resolution MRI with PNN‑sensitive contrast (e.g., w*‑imaging) will reveal reduced hippocampal CA2 PNN signal intensity.
4. Administration of a vagotomy blocker will abolish the cognitive and neuroimaging benefits, confirming the gut‑brain pathway.

Experimental Design

• Participants: 60 cognitively normal adults aged 65‑80, randomized to probiotic (Bifidobacterium longum + butyrate‑producing clade) or placebo for 12 weeks.
• Baseline & Follow‑up: Fecal metabolomics (δ‑valerobetaine, SCFAs), serum butyrate, EEG microstate analysis, neuropsychological battery (working memory, cognitive flexibility), and optional w*‑MRI subset (n=20).
• Intervention: Daily capsule delivering 10^9 CFU; compliance tracked via pill count and microbial sequencing.
• Analysis: Mixed‑effects models testing group × time interactions; mediation analysis to assess whether changes in δ‑valerobetaine explain microstate shifts, which in turn predict behavioral gains.

If the probiotic normalizes microbial metabolites, dampens microglial‑driven PNN deposition, and reinstates flexible brain dynamics, it would support the view that cognitive aging stems from over‑consolidation rather than irreversible loss, and that targeted gut‑brain modulation can re‑introduce the controlled uncertainty needed for adaptive cognition.